Status:
UNKNOWN
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Lead Sponsor:
China Medical University Hospital
Conditions:
Lung Adenocarcinoma
Eligibility:
All Genders
25-85 years
Brief Summary
AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role o...
Eligibility Criteria
Inclusion
- Lung cancer received operation lobectomy in CMUH
Exclusion
- History of uremia, other malignant disease, and liver cirrhosis
- History of pneumonia and pulmonary tuberculosis
- History of long period of medications.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01249066
Start Date
September 1 2010
Last Update
November 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fang Hsin Yuan
Taichung, Taiwan, 404